C. difficile Polysaccharide Vaccine Composition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for eliciting an immune response against Clostridioides difficile (C. difficile) infections are inadequate, as C. difficile can cause severe and life-threatening inflammation in the colon, and existing treatments do not effectively prevent recurrence.

Innovation Solution

A composition comprising a cell-surface polysaccharide from C. difficile, specifically the PSII antigen enriched from C. difficile, is developed. This composition can be combined with a first polypeptide comprising a carrier protein, and optionally with a second polypeptide comprising a toxoid of C. difficile, to enhance immune response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatment methods are used for C. difficile infection, then the infection can be treated, but the immune response is inadequate and recurrence occurs

Engineering Contradiction:

Improveeffectiveness of immune responseVSAvoidrecurrence of infection

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses a composite vaccine composition combining polysaccharide capsules from multiple C. difficile strains with carrier proteins and adjuvants. This composite approach creates a more comprehensive immune response that targets diverse strain variations, improving reliability while preventing recurrence better than single-component treatments

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent modifies the polysaccharide capsule structure by enriching for specific antigenic components and controlling the ratio of polysaccharide to carrier protein (1:1 to 10:1). These parameter changes optimize the immunogenicity and efficacy of the vaccine, enhancing immune response reliability

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If polysaccharide enrichment is increased to at least 90% of total carbohydrate, then the specificity of immune response improves, but the manufacturing complexity increases

Engineering Contradiction:

Improvespecificity of immune responseVSAvoidmanufacturing process complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent extracts and enriches specific polysaccharide capsule components from C. difficulte cells, isolating the PSII antigen and other capsule polysaccharides. This extraction process achieves high specificity (≥90% polysaccharide content) by removing non-target components while maintaining manufacturing feasibility through established purification techniques

Inventive Principle:

Principle #2Taking out (Extraction)

3Reliability

If the carrier protein to polysaccharide ratio is optimized to less than 10:1, then the immune response efficacy improves, but the formulation precision requirements increase

Engineering Contradiction:

Improveimmune response efficacyVSAvoidformulation ratio precision

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent optimizes the carrier protein to polysaccharide ratio parameter to fall within the range of 10:1 to 1:3, with preferred ranges of 5:1 to 2:1. This parameter optimization balances immune response efficacy with manufacturing feasibility, achieving reliable immunogenicity without requiring extreme precision in formulation

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250170162A9Methods and compositions for treating clostridiodes difficile infections

Publication Date: 2025.05.29 ELARIS FLEXCO

AI summary

Provided herein are immunogenic compositions for treating Clostridioides difficile infections.